StarkAge Therapeutics is focused on developing STX-1, a targeted therapy directed at senescent cells that arise following anti-cancer treatments. The company describes STX-1 as a promising candidate in this space. To accelerate that development, StarkAge announced a €1.2m fundraising in a press release on its LinkedIn page. The announcement did not disclose investors, financing instrument, or other financial metrics. No revenue, user, or other operating metrics were provided in the post. The company’s LinkedIn profile shows 1,029 followers.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

May 2024